Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28043548 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL26616615 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL1236838 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL9747592 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL21153537 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL1236602 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL29956930 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL3946404 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL10586641 | 1.00 | TSHR (0.58) | TSHRFAAHTRPV1HTTMEN1 | |
| SCHEMBL2030564 | 0.98 | TSHR (0.56) | TSHRFAAHTRPV1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | PNLIP, CPT1A, CPT1B | TSHR 2041/4885FAAH 1468/4885TRPV1 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.